Jazz Pharmaceuticals plc (JAZZ) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 6.67%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 6.67% | Share-based compensation / revenue. Period ending 2026-06-30. $306.73M ÷ $4.60B × 100 ≈ 6.67% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 4.60B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 306.73M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 896.86M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $4.60B | $306.73M | $896.86M | (m) | (m) | 6.67% | (m) | (m) |
| 2026-03-31 | (m) | $4.44B | $297.93M | $-37.74M | (m) | (m) | 6.71% | (m) | (m) |
| 2025-12-31 | (m) | $4.27B | $291.13M | $-430.24M | (m) | (m) | 6.82% | (m) | (m) |
| 2025-09-30 | (m) | $4.16B | $290.47M | $-494.00M | (m) | (m) | 6.99% | (m) | (m) |
| 2025-06-30 | (m) | $4.09B | $262.10M | $-291.30M | (m) | (m) | 6.41% | (m) | (m) |
| 2025-03-31 | (m) | $4.06B | $254.26M | $594.53M | (m) | (m) | 6.26% | (m) | (m) |
| 2024-12-31 | (m) | $4.07B | $248.04M | $716.63M | (m) | (m) | 6.10% | (m) | (m) |
| 2024-09-30 | (m) | $3.99B | $230.80M | $648.36M | (m) | (m) | 5.78% | (m) | (m) |
| 2024-06-30 | (m) | $3.91B | $227.15M | $560.54M | (m) | (m) | 5.81% | (m) | (m) |
| 2024-03-31 | (m) | $3.84B | $231.93M | $518.73M | (m) | (m) | 6.03% | (m) | (m) |
| 2023-12-31 | (m) | $3.83B | $226.84M | $578.58M | (m) | (m) | 5.92% | (m) | (m) |
| 2023-09-30 | (m) | $3.79B | $235.46M | $192.70M | (m) | (m) | 6.21% | (m) | (m) |
| 2023-06-30 | (m) | $3.76B | $236.02M | $45.07M | (m) | (m) | 6.27% | (m) | (m) |
| 2023-03-31 | (m) | $3.74B | $228.28M | $-27.02M | (m) | (m) | 6.11% | (m) | (m) |
| 2022-12-31 | (m) | $3.66B | $222.00M | $-65.53M | (m) | (m) | 6.07% | (m) | (m) |
| 2022-09-30 | (m) | $3.58B | $213.56M | $247.24M | (m) | (m) | 5.96% | (m) | (m) |
| 2022-06-30 | (m) | $3.48B | $210.12M | $250.84M | (m) | (m) | 6.04% | (m) | (m) |
| 2022-03-31 | (m) | $3.30B | $204.59M | $95.71M | (m) | (m) | 6.20% | (m) | (m) |
| 2021-12-31 | (m) | $3.09B | $189.01M | $170.28M | (m) | (m) | 6.11% | (m) | (m) |
| 2021-09-30 | (m) | $2.86B | $167.27M | $294.31M | (m) | (m) | 5.84% | (m) | (m) |
| 2021-06-30 | (m) | $2.63B | $144.39M | $462.15M | (m) | (m) | 5.50% | (m) | (m) |
| 2021-03-31 | (m) | $2.44B | $126.83M | $729.87M | (m) | (m) | 5.21% | (m) | (m) |
| 2020-12-31 | (m) | $2.36B | $121.00M | $378.07M | (m) | (m) | 5.12% | (m) | (m) |
| 2020-09-30 | (m) | $2.28B | $115.55M | $265.90M | (m) | (m) | 5.07% | (m) | (m) |
| 2020-06-30 | (m) | $2.22B | $113.98M | $202.80M | (m) | (m) | 5.14% | (m) | (m) |
| 2020-03-31 | (m) | $2.19B | $111.67M | $208.96M | (m) | (m) | 5.10% | (m) | (m) |
| 2019-12-31 | $299.73M | $2.16B | $110.56M | $532.37M | (m) | 13.86% | 5.11% | (m) | (m) |
| 2019-09-30 | $259.00M | $2.06B | $111.35M | $656.18M | (m) | 12.59% | 5.41% | (m) | (m) |
| 2019-06-30 | $230.31M | $1.99B | $107.67M | $711.86M | (m) | 11.58% | 5.42% | (m) | (m) |
| 2019-03-31 | $224.05M | $1.95B | $105.69M | $660.77M | (m) | 11.46% | 5.41% | (m) | (m) |
| 2018-12-31 | $226.62M | $1.89B | $102.44M | $614.84M | (m) | 11.98% | 5.42% | (m) | (m) |
| 2018-09-30 | $235.95M | $1.85B | $103.04M | $570.99M | (m) | 12.75% | 5.57% | (m) | (m) |
| 2018-06-30 | $232.16M | $1.79B | $105.06M | $468.67M | (m) | 12.95% | 5.86% | (m) | (m) |
| 2018-03-31 | $216.18M | $1.69B | $106.01M | $480.51M | (m) | 12.81% | 6.28% | (m) | (m) |
| 2017-12-31 | $198.44M | $1.62B | $106.90M | $528.84M | (m) | 12.26% | 6.60% | (m) | (m) |
| 2017-09-30 | $176.60M | $1.58B | $103.86M | $553.14M | (m) | 11.19% | 6.58% | (m) | (m) |
| 2017-06-30 | $177.04M | $1.54B | $101.61M | $602.94M | (m) | 11.49% | 6.59% | (m) | (m) |
| 2017-03-31 | $175.97M | $1.53B | $99.78M | $606.63M | (m) | 11.52% | 6.53% | (m) | (m) |
| 2016-12-31 | $162.30M | $1.49B | $98.77M | $591.65M | (m) | 10.91% | 6.64% | (m) | (m) |
| 2016-09-30 | $147.59M | $1.43B | $98.81M | $532.78M | (m) | 10.31% | 6.90% | (m) | (m) |
| 2016-06-30 | $150.58M | $1.40B | $97.05M | $528.06M | (m) | 10.76% | 6.94% | (m) | (m) |
| 2016-03-31 | $139.32M | $1.35B | $94.91M | $512.62M | (m) | 10.31% | 7.02% | (m) | (m) |
| 2015-12-31 | $135.25M | $1.32B | $91.55M | $508.22M | (m) | 10.21% | 6.91% | (m) | (m) |
| 2015-09-30 | $130.36M | $1.31B | $86.25M | $531.51M | (m) | 9.94% | 6.57% | (m) | (m) |
| 2015-06-30 | $102.00M | $1.28B | $81.39M | $458.01M | (m) | 7.98% | 6.37% | (m) | (m) |
| 2015-03-31 | $94.25M | $1.24B | $76.64M | $379.00M | (m) | 7.63% | 6.20% | (m) | (m) |
| 2014-12-31 | $85.18M | $1.17B | $69.64M | $195.59M | (m) | 7.26% | 5.94% | (m) | (m) |
| 2014-09-30 | $79.42M | $1.08B | $63.03M | $160.17M | (m) | 7.35% | 5.83% | (m) | (m) |
| 2014-06-30 | $68.82M | $1.01B | $56.66M | $202.69M | (m) | 6.84% | 5.63% | (m) | (m) |
| 2014-03-31 | $57.98M | $923.11M | $49.61M | $205.47M | (m) | 6.28% | 5.37% | (m) | (m) |
| 2013-12-31 | $46.62M | $872.42M | $44.55M | $340.31M | (m) | 5.34% | 5.11% | (m) | (m) |
| 2013-09-30 | $40.09M | $820.35M | $39.99M | $313.19M | (m) | 4.89% | 4.88% | (m) | (m) |
| 2013-06-30 | $34.19M | $763.71M | $34.73M | $267.93M | (m) | 4.48% | 4.55% | (m) | (m) |
| 2013-03-31 | $27.27M | $679.69M | $28.48M | $230.29M | (m) | 4.01% | 4.19% | (m) | (m) |
| 2012-12-31 | $20.48M | $585.98M | $23.01M | $197.84M | (m) | 3.49% | 3.93% | (m) | (m) |
| 2012-09-30 | $16.96M | $485.81M | $26.10M | $168.13M | (m) | 3.49% | 5.37% | (m) | (m) |
| 2012-06-30 | $13.32M | $394.78M | $22.68M | $140.01M | (m) | 3.37% | 5.74% | (m) | (m) |
| 2012-03-31 | $14.38M | $329.81M | $20.84M | $138.41M | $956.00K | 4.36% | 6.32% | 144.78× | Reported |
| 2011-12-31 | $14.12M | $272.28M | $20.70M | $127.83M | $1.68M | 5.19% | 7.60% | 76.32× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $189.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $25.61M | $173.78M | $8.22M | $57.79M | $12.73M | 14.74% | 4.73% | 4.54× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $36.56M | $128.45M | $5.96M | $15.93M | $22.80M | 28.46% | 4.64% | 0.70× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |